Firstly, PIK3CA mutations arm cancer cells with the immune checkpoint regulator programmed death-ligand 1 (PD-L1), which transmits an inhibitory signal and reduces the proliferation of antigen-specific CD8+ T cells through binding to programmed cell death protein 1 (PD-1). Here, PIK3CA is linked to cancer.